Follow the 케이바이오랩스 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 케이바이오랩스 has logged 50 public disclosures. Market capitalisation: €23.1bn. The latest transaction was reported on 16 July 2026 (Other). Among the most active insiders: 미래아이앤지. The full history is openly available.
40
Insider Decl.
n/a
Thresholds
n/a
5 ops.
Buy Volume
n/a
22 ops.
Sell Volume
Fundamental score
Ranked 21,221 of 29,063 companies
36.2
score / 100
Value
55
Quality
18
FCF yld35%
Earn yld-14%
EV/EBITDA·
ROE·
Gross mgn14%
Net mgn-3.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
케이바이오랩스 es una empresa del sector de la salud y farmacéutico, cotizada en el mercado XKRX. Se centra en el desarrollo de soluciones innovadoras para el campo médico.